What the company does
Nextbiomedical develops medical products that stop bleeding during endoscopic procedures and block blood vessels to treat tumors, using polymer and drug-delivery technology as their foundation.
Its products are used by physicians in hospitals, and it distributes them through licensing agreements with larger medical-device companies in major markets including the United States, Europe, and Japan. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company's commercial revenue is currently anchored by its endoscopic hemostatic powder, Nexpowder™, which is distributed globally under a licensing deal with Medtronic.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2024US$6.9M
- FY2025US$11.9M
Operating profit
- FY2024−US$2.6M
- FY2025−US$521.4K
Net income
- FY2024US$2.1M
- FY2025−US$225.4K
Key ratios (FY2025)
Why it matters · Context, not a recommendation
Nextbiomedical has a quality-management system partnership with Medtronic and holds domestic distribution rights through Taewong Medical for the Korean market.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?